Azitra Taps Microbiome For Dermatology Therapies, Including Cancer Supportive Care

Azitra Inc. is nearing the clinic with its initial two programs based on harnessing the microbiome to address dermatological conditions, but the privately held company also has a second potential stream of income through a partnership inked in 2019 with Bayer AG to apply its technology to cosmetics.

Founded in 2014 and based on research performed at Yale University by co-founder Travis Whitfill, now the biotech’s executive director of advanced technology, Azitra is developing a live strain of Staphylococcus epidermidis as a topical treatment for cancer therapy-associated rashes